BR112022002856A2 - Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque - Google Patents
Orientação de terapia e/ou monitoramento de terapia para o tratamento de choqueInfo
- Publication number
- BR112022002856A2 BR112022002856A2 BR112022002856A BR112022002856A BR112022002856A2 BR 112022002856 A2 BR112022002856 A2 BR 112022002856A2 BR 112022002856 A BR112022002856 A BR 112022002856A BR 112022002856 A BR112022002856 A BR 112022002856A BR 112022002856 A2 BR112022002856 A2 BR 112022002856A2
- Authority
- BR
- Brazil
- Prior art keywords
- shock
- therapy
- individual
- dpp3
- level
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
ORIENTAÇÃO DE TERAPIA E/OU MONITORAMENTO DE TERAPIA PARA O TRATAMENTO DE CHOQUE. A presente invenção refere-se a um método para predizer ou diagnosticar um choque refratário em um indivíduo que está em choque ou que desenvolveu o choque, em que o dito método compreende as etapas de: determinação do nível de DPP3 em uma amostra do fluido corpóreo do dito indivíduo; comparação do dito nível de DPP3 determinado a um limite predeterminado, em que é predito que o dito indivíduo está em choque refratário ou foi diagnosticado como tendo choque refratário se o dito nível de DPP3 determinado estiver acima do dito limite predeterminado. Além disso, o objeto refere-se a vasopressores, agonistas de receptor de angiotensina e/ou seus precursores, a inibidores da atividade de DPP3 e a anticorpos anti-ADM para o uso na terapia de choque em um indivíduo que está em choque ou que desenvolveu o choque.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19194729 | 2019-08-30 | ||
EP19201098 | 2019-10-02 | ||
PCT/EP2020/074134 WO2021038078A1 (en) | 2019-08-30 | 2020-08-28 | Therapy guidance and/or therapy monitoring for treatment of shock |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022002856A2 true BR112022002856A2 (pt) | 2022-08-09 |
Family
ID=72292531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022002856A BR112022002856A2 (pt) | 2019-08-30 | 2020-08-28 | Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220307065A1 (pt) |
EP (1) | EP4021571A1 (pt) |
JP (1) | JP2022546061A (pt) |
CN (1) | CN114556100A (pt) |
AU (1) | AU2020338818A1 (pt) |
BR (1) | BR112022002856A2 (pt) |
CA (1) | CA3148275A1 (pt) |
MX (1) | MX2022002432A (pt) |
WO (1) | WO2021038078A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3168978A1 (en) * | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
RU2754731C1 (ru) * | 2021-02-19 | 2021-09-06 | Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития тяжелого течения неонатального дистрибутивного шока у глубоконедоношенных новорожденных с массой тела при рождении менее 1500 г |
WO2024023368A1 (en) * | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
US7064107B2 (en) | 2002-06-07 | 2006-06-20 | Dyax Corp. | Prevention and reduction of blood loss |
AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
US8278262B2 (en) | 2004-09-21 | 2012-10-02 | Biontech Ag | Use of microproteins as tryptase inhibitors |
DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
WO2010060748A1 (en) | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
AU2010288542B2 (en) | 2009-08-27 | 2014-05-22 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
EP2379581B1 (en) | 2009-12-14 | 2013-10-09 | Scil Proteins GmbH | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
CN111499725A (zh) | 2010-06-08 | 2020-08-07 | 皮里斯制药有限公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
ES2494191T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para su utilización en tratamientos |
SG11202002258WA (en) | 2017-09-25 | 2020-04-29 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
JP2021500548A (ja) * | 2017-10-18 | 2021-01-07 | アドレノメト アクチェンゲゼルシャフト | 抗アドレノメデュリン(adm)結合剤での処置下での治療モニタリング |
-
2020
- 2020-08-28 CA CA3148275A patent/CA3148275A1/en active Pending
- 2020-08-28 EP EP20764639.9A patent/EP4021571A1/en active Pending
- 2020-08-28 BR BR112022002856A patent/BR112022002856A2/pt unknown
- 2020-08-28 WO PCT/EP2020/074134 patent/WO2021038078A1/en unknown
- 2020-08-28 MX MX2022002432A patent/MX2022002432A/es unknown
- 2020-08-28 US US17/637,518 patent/US20220307065A1/en active Pending
- 2020-08-28 AU AU2020338818A patent/AU2020338818A1/en active Pending
- 2020-08-28 CN CN202080060609.1A patent/CN114556100A/zh active Pending
- 2020-08-28 JP JP2022513298A patent/JP2022546061A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020338818A1 (en) | 2022-03-31 |
WO2021038078A1 (en) | 2021-03-04 |
US20220307065A1 (en) | 2022-09-29 |
EP4021571A1 (en) | 2022-07-06 |
CN114556100A (zh) | 2022-05-27 |
CA3148275A1 (en) | 2021-03-04 |
MX2022002432A (es) | 2022-06-02 |
JP2022546061A (ja) | 2022-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022002856A2 (pt) | Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque | |
BR112013006764A2 (pt) | método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente | |
MX2018003376A (es) | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. | |
MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
BR112019004075A2 (pt) | métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit. | |
NZ619918A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
BR112013019563A2 (pt) | métodos para prognóstico de ferida, para tratamento de ferida, para prognosticar se um paciente pode ser responsivo ao tratamento de uma ferida que exsuda um fluido de ferida, e para tratar uma ferida que exsuda um fluido de ferida, dispositivo para medir simultaneamente ou sequencialmente os níveis de hne e de pelo menos uma mmp em uma amostra de fluido de ferida, aparelho para diagnóstico, e, estojo. | |
MX2020001193A (es) | Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. | |
BR112017010268A2 (pt) | agente de ligação; composição de diagnóstico; kit de diagnóstico; métodos de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral; para descartar uma infecção bacteriana em um indivíduo; para descartar uma infecção viral em um indivíduo; para considerar uma infecção bacteriana em um indivíduo; para considerar uma infecção viral em um indivíduo; para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo; para fornecer uma recomendação de tratamento para um indivíduo; para fornecer uma recomendação de teste de diagnóstico para um indivíduo; para descartar uma doença infecciosa; para identificação do tipo de infecção; e dispositivo para o diagnóstico de infecções bacterianas | |
BR112015008042A2 (pt) | diagnósticos complementares para terapia com inibidor de quinase da família tec | |
AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
BR112015025407A2 (pt) | método e dispositivo para testar um transformador | |
BR112015026242A2 (pt) | dispositivo de coleta de fluido biológico e sistema de separação e testagem de fluido biológico | |
BR112016019740A2 (pt) | monitoramento do estado de inflamação | |
BR112017022320A2 (pt) | métodos para tratamento de câncer de pulmão | |
ES2723710T3 (es) | Sistema y método para una prueba de presión de referencia | |
BR112014020213A2 (pt) | biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope | |
IN2014DE01077A (pt) | ||
EA201790696A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности | |
NZ606124A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
BR112019000199A2 (pt) | adrenomedulina para avaliar a congestão em um indivíduo com insuficiência cardíaca aguda | |
JP2017508144A5 (pt) | ||
BR112023000892A2 (pt) | Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor |